

# Canakinumab

## Adjudication Guideline

<b>Rule Category:</b> Pharmaceutical	<b>Ref: No:</b> 2022-PH-014	<b>Version Control:</b> Version No.3	<b>Effective Date:</b> 30/01/2023	<b>Revision Date:</b> 22/11/2025
<b>Approved by:</b> Daman	<b>Responsible:</b> Pharmaceutical Standards	<b>Related Adjudication Guidelines:</b> N/A & Governance		

## Table of Contents

1. Abstract .....	3
1.1 For Members.....	3
1.2 For Medical Professionals.....	3
2. Scope .....	3
3. Adjudication Policy.....	3
3.1 Eligibility / Coverage Criteria.....	3
3.2 Requirements for Coverage .....	4
3.3 Non-Coverage.....	4
3.4 Payment and Coding Rules .....	5
4. Denial Codes.....	5
5. Appendices .....	5
5.1 References .....	5
5.2 Revision History .....	5

## 1. Abstract

### 1.1 For Members

Canakinumab is used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).

### 1.2 For Medical Professionals

Canakinumab is an interleukin-1 $\beta$  (IL-1 $\beta$ ) blocker, which works to suppress the production of an inflammatory protein in the body. IL-1 $\beta$  is a pro-inflammatory protein released in states of infection and inflammation. Overproduction of IL-1 $\beta$  creates inflammation in the body resulting in symptoms such as fever, joint pain, and rashes. Canakinumab is a human monoclonal antibody which binds to the IL-1 $\beta$  protein and prevents it from attaching to its cellular receptor.

## 2. Scope

The scope of this adjudication rule is to highlight the medical indications, and coverage details for Canakinumab as per the policy terms and conditions of each health insurance plan administered by Daman.

## 3. Adjudication Policy

### 3.1 Eligibility / Coverage Criteria

Canakinumab is an interleukin-1 $\beta$  blocker indicated for the treatment of the following:

1. autoinflammatory Periodic Fever Syndromes in adults, adolescents and children aged 2 years and older:
  - a) Cryopyrin-associated periodic syndromes (CAPS):  
Canakinumab is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:
    - Muckle-Wells syndrome (MWS),
    - Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),
    - Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
  - b) Tumour necrosis factor receptor associated periodic syndrome (TRAPS):  
Canakinumab is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Physician's Global Assessment score greater than or equal to 2, or C-reactive protein (CRP) greater than 10 mg/L .
  - c) Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD):  
Canakinumab is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). Physician's Global Assessment score greater than or equal to 2, or C-reactive protein (CRP) greater than 10 mg/L.

d) Familial Mediterranean fever (FMF):

Canakinumab is indicated for the treatment of Familial Mediterranean Fever (FMF). It should be given in combination with colchicine, if appropriate. Physician's Global Assessment score greater than or equal to 2, or C-reactive protein (CRP) greater than 10 mg/L.

2. Still's disease

Canakinumab is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD).

3. Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Canakinumab can be given as monotherapy or in combination with methotrexate.

4. Gouty arthritis:

Canakinumab is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attack (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

5. Gout flares

Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate

#### Assessment Prior to Initiating

- Tuberculosis (TB) test within the past 12 months is negative, or if positive, active TB has been ruled out and the patient has received treatment for latent TB infection <sup>1,2</sup>.
- Known hypersensitivity to any component of Canakinumab.
- Active infection, including localized infections.

## 3.2 Requirements for Coverage

- Failure to submit, upon request or when requesting a clinical history, indication the need for testing will result in rejection of claim.
- Kindly code the ICD-10 and the CPT codes to the highest level of specificity
- Eligible clinician specialities

Eligible clinician specialities
Rheumatologist
Internal medicine
Paediatrics

## 3.3 Non-Coverage

- Non- FDA approved indication
- Age less than 2 years

### 3.4 Payment and Coding Rules

- Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

## 4. Denial Codes

Code	Code Description
CODE-010	Activity/diagnosis inconsistent with clinician's speciality
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnosis/activities
MNEC-005	Service/supply may be appropriate, but too frequent
CLAI-012	Submission not compliant with contractual agreement between provider & payer
PRCE-002	Payment is included in the allowance for another service.
CODE-014	Activity/diagnosis is inconsistent with the patient's age/gender

## 5. Appendices

### 5.1 References

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/BLA125319\\_858687lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/BLA125319_858687lbl.pdf)  
[https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf)  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/125319s107lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125319s107lbl.pdf)  
<https://www.medicines.org.uk/emc/product/8874/smpc#qref>  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/125319s110lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125319s110lbl.pdf)

### 5.2 Revision History

Date	Version No.	Change(s)
27/12/2022	V1.0	Release of V1.0
4/11/2024	V2.0	No changes / updated in the new format
22/11/2025	V3.0	Guideline review/ No changes-new references added

## Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below: The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.